INA03
Advanced cancers
PreclinicalActive
Key Facts
About Inatherys
Inatherys is a Paris-based, private biotech focused on developing monoclonal antibodies for high-need oncology and inflammatory diseases. Its lead programs, INA02 and INA03, are in preclinical development, targeting CD89 and CD71 receptors, respectively, to address conditions with limited therapeutic options. The company leverages strong academic roots from INSERM and Necker Hospital, with a management team combining deep scientific expertise and pharmaceutical industry experience. Inatherys operates as a pre-revenue, preclinical-stage company seeking to advance its candidates into clinical trials.
View full company profileTherapeutic Areas
Other Advanced cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| MDX2004 | Opko Health | Phase 1 |
| DC-6001 (DCBY02) | DynamiCure | Phase 1 |
| DC-6001 (DCSZ11) | DynamiCure | Phase 1 (Planned) |
| IBI-110 | Innovent Biologics | Phase 2 |
| NXP900 | Nuvectis Pharma | Phase 1 |